HORSHAM, Pa.--(BUSINESS WIRE)--Feb. 9, 2006--Neose Technologies, Inc. (NasdaqNM:NTEC) today announced that it received a research milestone payment from Novo Nordisk A/S (NYSE:NVO) under its recently expanded license agreement for the use of Neose’s GlycoPEGylation(TM) technology to develop a next-generation version of a therapeutic protein currently marketed by Novo Nordisk.
